Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Myriad Genetics Inc

MYGN
Current price
7.42 USD +0.11 USD (+1.50%)
Last closed 7.29 USD
Company myriad.com
ISIN US62855J1043
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 679 303 232 USD
Yield for 12 month -62.53 %
1Y
3Y
5Y
10Y
15Y
MYGN
21.11.2021 - 28.11.2021

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Address: 322 North 2200 West, Salt Lake City, UT, United States, 84116

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.82 USD

P/E ratio

Dividend Yield

Current Year

+837 600 000 USD

Last Year

+753 200 000 USD

Current Quarter

+210 600 000 USD

Last Quarter

+213 300 000 USD

Current Year

+585 400 000 USD

Last Year

+517 000 000 USD

Current Quarter

+150 900 000 USD

Last Quarter

+149 800 000 USD

Key Figures MYGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -26 800 000 USD
Operating Margin TTM -8.22 %
Price to Earnings
Return On Assets TTM -5.06 %
PEG Ratio 1.40
Return On Equity TTM -17.15 %
Wall Street Target Price 15.82 USD
Revenue TTM 837 600 000 USD
Book Value 7.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 7.10 %
Dividend Yield
Gross Profit TTM 585 400 000 USD
Earnings per share -1.41 USD
Diluted Eps TTM -1.41 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin -15.20 %

Dividend Analytics MYGN

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History MYGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years 0
Consistent Years 0
Continuous Dividends 0
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 2:1
Payout Ratio TTM
Last Split Date 26.03.2009

Stock Valuation MYGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 93.46
Enterprise Value Revenue 0.85
Price Sales TTM 0.81
Enterprise Value EBITDA -23.47
Price Book MRQ 0.96

Financials MYGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators MYGN

For 52 weeks

7.16 USD 29.30 USD
50 Day MA 10.06 USD
Shares Short Prior Month 5 092 357
200 Day MA 18.23 USD
Short Ratio 5.53
Shares Short 5 363 278
Short Percent 8.21 %